- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02221700
위장관 또는 유방 악성 종양 환자의 화학 요법으로 유발된 말초 신경병증 감소를 위한 마사지 요법
화학 요법으로 유발된 말초 신경병증의 증상 감소를 위한 마사지의 파일럿 연구
This clinical trial studies massage therapy in reducing chemotherapy-induced nerve problems (peripheral neuropathy) that may cause pain, numbness, tingling, swelling, or muscle weakness in different parts of the body in patients with gastrointestinal or breast malignancies. Massage therapy may help reduce chemotherapy-induced peripheral neuropathy symptoms and improve quality of life.
연구 개요
상태
상세 설명
PRIMARY OBJECTIVES; I. To compare completion rates of two massage treatment protocols (twice-weekly for 6 weeks versus three times weekly for 4 weeks) for patients with chronic, chemotherapy-induced peripheral neuropathy.
SECONDARY OBJECTIVES:
I. To determine the initial efficacy and effect size estimates of twice versus three times weekly site specific (lower extremity) massage versus alternate massage site (head/neck/shoulder) control groups at treating chronic, lower extremity chemotherapy-induced peripheral neuropathy.
II. To determine the initial efficacy and effect size estimates of massage on patient quality of life and functional performance tests.
OUTLINE: Patients are randomized to 1 of 4 groups.
GROUP I: Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, thrice weekly for 4 weeks.
GROUP II: Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, twice weekly for 6 weeks.
GROUP III: Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder thrice weekly for 4 weeks.
GROUP IV: Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder twice weekly for 6 weeks.
After completion of study, patients are followed periodically.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030
- M D Anderson Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
All gastrointestinal malignancies where the patient received oxaliplatin for cancer treatment or breast malignancies where patients have received docetaxel or paclitaxel for cancer treatment
-
Greater or equal to 6 months from last chemotherapy treatment
-
Must understand and read English, sign a written informed consent, and follow protocol requirements
-
Must be willing to come to MD Anderson Main Campus (Texas Medical Center) for intervention
-
Lower extremity neuropathy per patient report attributable to oxaliplatin, docetaxel or paclitaxel (neurotoxic chemotherapeutic agent) as determined by patient history of neurotoxic agent administration and no history of other attributable causes such as diabetic neuropathy
-
Patient self-report neuropathy score greater than or equal to 3 on a 0 to 10 numeric scale and/or grade 2 or 3 neuropathy (according to the National Cancer Institute Common Toxicity Criteria 4 point grading scale)
-
Within 2 weeks prior to study enrollment the patient must be on a stable dose of medications for management of chemotherapy-induced peripheral neuropathy (CIPN) symptoms; for at least 2 weeks prior to enrollment stable dose is defined as:
- No change in drug class
- Increases or decreases that are less than or equal to 20% of the total dosage; all drug classes are allowed
Exclusion Criteria:
- Patients with previously diagnosed peripheral neuropathy pre-dating their neurotoxic chemotherapy administration or from causes other than chemotherapy
- Platelets less than 50,000 within 6 months prior to study enrollment or
- Neutrophil count less than 500 within 6 months prior to study enrollment
- Deep venous thrombosis (DVT) diagnosed within 12 months of study enrollment or history or untreated lower extremity DVT, bone metastases, currently active skin infection, or lymphedema currently involving the treatment field
- Women who are pregnant at time of enrollment; pregnancy will be assessed at enrollment using urine pregnancy test
- Diagnosis of diabetes
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Group I (leg massage 3 x weekly for 4 weeks)
Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, thrice weekly for 4 weeks. |
Ancillary studies
다른 이름들:
Ancillary studies Undergo massage therapy
다른 이름들:
|
|
실험적: Group II (leg massage 2 x weekly for 6 weeks)
Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, twice weekly for 6 weeks. |
Ancillary studies
다른 이름들:
Ancillary studies Undergo massage therapy
다른 이름들:
|
|
실험적: Group III (head/neck/shoulder massage 3 x weekly for 4 weeks)
Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder thrice weekly for 4 weeks. |
Ancillary studies
다른 이름들:
Ancillary studies Undergo massage therapy
다른 이름들:
|
|
실험적: Group IV (head/neck/shoulder massage 2 x weekly for 6 weeks)
Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder twice weekly for 6 weeks. |
Ancillary studies
다른 이름들:
Ancillary studies Undergo massage therapy
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Completion Rates of Two Massage Treatment Protocols for Patients With Chronic, Oxaliplatin-Induced Peripheral Neuropathy
기간: 10 weeks
|
Completion rate defined as the average number of treatments completed of a possible 12 for patients in each protocol. Mean and standard deviation, along with a 95% confidence interval (CI) of the mean of the number of massages completed for each of the two massage schedules computed. Two-sample t-test used to compare the number of massages completed between the two schedules using a two-sided 0.05 significance level. |
10 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Quality and intensity of neuropathic pain
기간: At 10 weeks
|
Will be measured by Pain Quality Assessment Scale (PQAS). To estimate the efficacy of the massage treatments at 10 weeks, linear regression will be used with PQAS as the dependent variable, massage site and schedule being two binary independent variables with interaction, adjusting for appropriate covariates such as the baseline value of PQAS. To assess the efficacy of the massage treatments over time linear mixed models (LMMs) will be used. |
At 10 weeks
|
|
Quality of life (QOL)
기간: Up to 10 weeks
|
Will be measured by the Medical Outcomes Study Short Form 36. Pairwise comparisons between arms will be made as desirable, adjusting for multiple comparisons using the Bonferroni approach. Similar linear regression and LMM analyses will be carried out for the QOL and function measures. |
Up to 10 weeks
|
|
Function and balance
기간: Up to 10 weeks
|
Will be measured by the Timed Up and Go test, the Single Limb Stance, and the Activities-Specific Balance Confidence Scale. Pairwise comparisons between arms will be made as desirable, adjusting for multiple comparisons using the Bonferroni approach. Similar linear regression and LMM analyses will be carried out for the QOL and function measures. |
Up to 10 weeks
|
|
Symptoms associated specifically with chemotherapy-induced peripheral neuropathy
기간: Up to 10 weeks
|
Will be assessed using the Functional Assessment of Cancer Therapy/Gynecological Oncology Group-neurotoxicity version 4 questionnaire. Pairwise comparisons between arms will be made as desirable, adjusting for multiple comparisons using the Bonferroni approach. Similar linear regression and LMM analyses will be carried out for the QOL and function measures. |
Up to 10 weeks
|
|
Baseline treatment expectations
기간: Baseline
|
Baseline treatment expectations will be assessed as a predictor of the secondary measures at week 10. |
Baseline
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Gabriel Lopez, M.D. Anderson Cancer Center
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .